JMP Securities analyst Reni Benjamin reiterated a Buy rating on Compugen (CGEN – Research Report) today and set a price target of $18.00. The company’s shares closed last Friday at $5.87, close to its 52-week low of $5.60.
According to TipRanks.com, Benjamin is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.4% and a 35.9% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics.
Compugen has an analyst consensus of Moderate Buy, with a price target consensus of $18.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $15.16 and a one-year low of $5.60. Currently, Compugen has an average volume of 988.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.
Read More on CGEN: